Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Denali Therapeutics Inc.
  6. Summary
    DNLI   US24823R1059

DENALI THERAPEUTICS INC.

(DNLI)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
32.73 USD   +3.31%
07/05DENALI THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
AQ
06/24DENALI THERAPEUTICS INC.(NASDAQGS : DNLI) dropped from Russell 2000 Defensive Index
CI
06/24DENALI THERAPEUTICS INC.(NASDAQGS : DNLI) dropped from Russell 2000 Growth-Defensive Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
28.98(c) 29.43(c) 31.24(c) 31.68(c) 32.73(c) Last
434 940 426 714 492 902 711 145 501 381 Volume
-1.09% +1.55% +6.15% +1.41% +3.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 104 M - -
Net income 2022 -327 M - -
Net cash position 2022 1 362 M - -
P/E ratio 2022 -12,2x
Yield 2022 -
Sales 2023 180 M - -
Net income 2023 -336 M - -
Net cash position 2023 1 222 M - -
P/E ratio 2023 -12,9x
Yield 2023 -
Capitalization 4 024 M 4 024 M -
EV / Sales 2022 25,6x
EV / Sales 2023 15,6x
Nbr of Employees 380
Free-Float 79,5%
More Financials
Company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator... 
Read more
More about the company
Ratings of Denali Therapeutics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DENALI THERAPEUTICS INC.
07/05DENALI THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
AQ
06/24DENALI THERAPEUTICS INC.(NASDAQGS : DNLI) dropped from Russell 2000 Defensive Index
CI
06/24DENALI THERAPEUTICS INC.(NASDAQGS : DNLI) dropped from Russell 2000 Growth-Defensive Index
CI
06/23Berenberg Bank Initiates Coverage on Denali Therapeutics With Buy Rating, $39 Price Tar..
MT
06/14TRANSCRIPT : Denali Therapeutics Inc. Presents at Goldman Sachs 43rd Annual Global Healthc..
CI
06/03DENALI THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders, Financial ..
AQ
05/31Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor..
GL
05/31Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor..
AQ
05/30Pharmenable Limited Announces Multi-Target Collaboration with Denali Therapeutics Inc. ..
CI
05/24Goldman Sachs Adjusts Denali Therapeutics Price Target to $82 From $99, Maintains Buy R..
MT
05/06Wedbush Adjusts Denali Therapeutics' Price Target to $48 From $62, Keeps Outperform Rat..
MT
05/05Earnings Flash (DNLI) DENALI THERAPEUTICS Posts Q1 Revenue $42.1M
MT
05/05DENALI THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
05/05Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlight..
GL
05/05Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlight..
AQ
More news
News in other languages on DENALI THERAPEUTICS INC.
07/05En medio de la suspensión de la FDA, Denali pone en marcha un estudio sobre el Alzheime..
05/30Pharmenable Limited annonce une collaboration multi-cibles avec Denali Therapeutics Inc..
05/05Earnings Flash (DNLI) DENALI THERAPEUTICS affiche un chiffre d'affaires de 42,1 million..
05/05Denali Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
05/02Denali Therapeutics et Sanofi démarrent un essai de phase 2 pour un inhibiteur de la SL..
More news
Analyst Recommendations on DENALI THERAPEUTICS INC.
More recommendations
Chart DENALI THERAPEUTICS INC.
Duration : Period :
Denali Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DENALI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 32,73 $
Average target price 68,92 $
Spread / Average Target 111%
EPS Revisions
Managers and Directors
Ryan J. Watts President, Chief Executive Officer & Director
Alexander O. Schuth Secretary, Chief Operating & Financial Officer
Vicki L. Sato Director
Carole Ho Chief Medical Officer & Head-Development
Dana Andersen CTO & Chief Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
DENALI THERAPEUTICS INC.-26.61%4 024
GILEAD SCIENCES, INC.-13.61%78 683
VERTEX PHARMACEUTICALS32.59%74 466
REGENERON PHARMACEUTICALS, INC.-5.80%64 098
WUXI APPTEC CO., LTD.-4.67%49 112
BIONTECH SE-37.86%38 932